Why Xeris Biopharma Holdings, Inc. (XERS) stock rose 25.1% on Thursday, November 5, 2026

Xeris Biopharma Holdings, Inc. (XERS) closed at $13.08, up 25.05% on Thursday, November 5, 2026, on volume of 12,296,693 shares (5.1× its 3-month average); market value about $2.40B.

What happened: primary sources

Events Nexqual found for XERS on Thursday, November 5, 2026 or the trading day before (November 4, 2026):

• Nov 5, 2026: Reported Q3 2026 results: EPS $0.06 vs consensus $0.03 (beat), revenue $107.2M vs consensus $101.7M (beat). Guidance: Full-year 2026 total revenue guidance is $395 million to $405 million. source
• Nov 2, 2026: Form 4: Pieper Steven (See Remarks) sold 5,000 shares ($51,174) under a Rule 10b5-1 plan source
• Nov 2, 2026: Form 4: Hecht Beth (See Remarks) sold 25,000 shares ($255,828) under a Rule 10b5-1 plan source
• Nov 2, 2026: Form 4: McCulloch Kevin (See Remarks) sold 15,000 shares ($153,488) under a Rule 10b5-1 plan source

These are listed as context. A filing or rating change on the same day is not proof that it caused the move; read the source.

More on XERS

XERS stock page: price, SEC financials, insider trades, superinvestor holders, analyst estimates and options. Earnings report: XERS results, November 5, 2026. Other big moves that day: November 5, 2026.

Sources: SEC EDGAR, Nexqual Earnings Flash, analyst rating changes, Nexqual market data. Built November 10, 2026 at 16:40 UTC. Not investment advice.

Data source: Nexqual. Last updated: November 10, 2026 at 16:40 UTC. This page is informational and not investment advice.

For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt